Table 1. Selected cases for WES and WTS analysis: demographic characteristics of the patient population at the time of diagnosis, and molecular characterization of the glioblastoma tumors.

RFS Month	RFS ID	ID Sample	Age	Sex	Tumor Size (cm2)	Brain Region	EGFR	EGFRvIII	MGMT	IDH1/2	RNAseq (WTS)	Exome Seq (WES)
2	S	A	58	F	70	Frontal	AMPL	Trunc.	MET	WT	X	X
3	S	B	60	F	52	Parietal	Not AMPL	WT	UNMET	WT	X	X
3	S	C	58	F	33	Right- temporal	AMPL	WT	MET	WT	X	X
5	S	D	62	M	7	Right-insula	Not AMPL	WT	UNMET	WT	X
5	S	E	70	M	28	Left-prerolandic (frontal)	Not AMPL	WT	MET	WT	X	X
5	S	F	58	F	146	Right frontal	Not AMPL	WT	UNMET	WT	X
16	M	G	58	M	90	ND	AMPL	WT	MET	WT	X
18	M	H	56	M	13	ND	Not AMPL	WT	UNMET	WT	X
23	M	I	60	F	48	Basal temporal lobe	AMPL	Trunc.	MET	WT	X
25	L	J	61	M	17	ND	Not AMPL	WT	UNMET	WT	X	X
30	L	K	57	F	33	Frontal	AMPL	WT	MET	WT	X	X
32	L	L	44	F	3	Frontal	AMPL	Trunc.	MET	WT	X	X
42	L	M	50	F	16	ND	ND	WT	UNMET	WT	X	X

RFS, recurrence-free survival; S, short group; M, medium group; L, long group; letters from A to M represents each ID samples; WES, whole exome sequencing; WTS, whole transcriptome sequencing; EGFR, epidermal growth factor receptor; EGFRvIII, EGFR variant III; MGMT, O(6)methylguanine-DNA methyltransferase; IDH1, isocitrate dehydrogenase1; MET, methylation; UNMET, no methylation; Trunc, presence of truncated form; AMPL, amplified; WT, wildtype; ND, not determined.